Enanta/$ENTA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Enanta
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
- Ticker
- $ENTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 120
- Headquarters
- Watertown, United States
- Website
- www.enanta.com
Enanta Metrics
BasicAdvanced
$320M
-
-$2.34
0.93
-
Price and volume
Market cap
$320M
Beta
0.93
52-week high
$17.15
52-week low
$10.05
Average daily volume
275K
Financial strength
Current ratio
3.759
Quick ratio
3.619
Long term debt to equity
1.399
Total debt to equity
1.801
Interest coverage (TTM)
-4.55%
Profitability
EBITDA (TTM)
-53.819
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-96.89%
Operating margin (TTM)
-89.99%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-12.28%
Return on equity (TTM)
-70.12%
Valuation
Price to revenue (TTM)
4.562
Price to book
3.17
Price to tangible book (TTM)
3.17
Price to free cash flow (TTM)
-8.059
Free cash flow yield (TTM)
-12.41%
Free cash flow per share (TTM)
-1.365
Growth
Revenue change (TTM)
0.70%
Earnings per share change (TTM)
-45.82%
3-year revenue growth (CAGR)
-6.79%
10-year revenue growth (CAGR)
-3.15%
3-year earnings per share growth (CAGR)
-28.23%
10-year earnings per share growth (CAGR)
4.47%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Analyst projections of the future price of Enanta stock.
Bulls say / Bears say
Enanta has started the registrational Phase 2b/3 RESOLVE trial of zelicapavir, aiming at high-risk adults with RSV, for whom no antiviral treatment is approved. In an earlier study, the selected subgroup had symptom resolution 6.7 days sooner and RSV-related hospitalisations of 0% versus 5% on placebo; the new trial will test whether that signal holds. (BusinessWire)
The paediatric programme broadens zelicapavir’s opportunity: Enanta has begun the LOTUS Phase 2b trial in children, following an earlier study that showed antiviral activity and shorter symptom duration. Topline results are expected in 2027, adding a further clinical catalyst. (Enanta Pharmaceuticals)
Enanta reported $211.5 million in cash and marketable securities and expects its cash plus retained royalties to fund current programmes into fiscal 2029. That runway gives it time to pursue upcoming clinical milestones without an immediate need to raise capital. (Enanta Pharmaceuticals)
Zelicapavir previously failed to show a benefit in the broader adult mid-stage trial, and its continued development relies on a favourable subgroup analysis. The subgroup’s size and statistical detail were not reported in the latest trial announcement, leaving the upcoming study to prove the signal is reliable. (Fierce Biotech, Mugglehead)
Revenue depends on AbbVie’s MAVYRET/MAVIRET HCV sales: Enanta’s quarterly royalties fell to $14.4 million from $18.3 million a year earlier as AbbVie’s sales declined. Enanta also sends 54.5% of the associated cash royalties to OMERS through June 2032, limiting the cash it keeps. (SEC)
The company continues to lose money while advancing unapproved drugs: it reported a $44.5 million net loss and $28.8 million of operating cash outflow for the first nine months of fiscal 2026. Enanta says it may seek additional funding, which could dilute shareholders if royalty income and cash prove insufficient. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Enanta News
AllArticlesVideos
Funds containing Enanta
Fund name | Fund size | $ENTA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.